E-cadherin expression is associated with somatostatin analogue response in acromegaly by Venegas Moreno, Eva et al.
OR I G I N A L A R T I C L E
E‐cadherin expression is associated with somatostatin
analogue response in acromegaly
Eva Venegas-Moreno1 | Alvaro Flores-Martinez1 | Elena Dios1 |
Mari C. Vazquez-Borrego2,3,4,5 | Alejandro Ibañez-Costa2,3,4,5 | Ainara Madrazo-Atutxa1 |
Miguel A. Japón6,7 | Justo P. Castaño2,3,4,5 | Raúl M. Luque2,3,4,5 | David A. Cano1 |
Alfonso Soto-Moreno1
1Unidad de Gestión de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de
Sevilla, Sevilla, Spain
2Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
3Department of Cell Biology, Physiology and Immunology, Universidad de Córdoba, Córdoba, Spain
4Hospital Universitario Reina Sofía, Córdoba, Spain
5CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Córdoba, Spain
6Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
7Department of Pathology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Correspondence: David A. Cano and Alfonso
Soto Moreno, Unidad de Gestión de
Endocrinología y Nutrición, Instituto de
Biomedicina de Sevilla (IBiS), Consejo
Superior de Investigaciones Científicas,
Universidad de Sevilla. Avda. Manuel Siurot,
s/n. Hospital Universitario Virgen del Rocío,
41013 Sevilla, Spain (dcano-ibis@us.es);
(alfonsom.soto.sspa@juntadeandalucia.es).
Funding information
ISCIII-Subdirección General de Evaluación y
Fomento de la Investigación co-funded with
Fondos FEDER, Grant/Award Number: PI13/
02043, PI16/00175; Junta de Andalucía,
Grant/Award Number: A-0023-2015, A-
0003-2016, CTS-1406, BIO-0139;
CIBERobn, Grant/Award Number: PI13/
02043, PI16/00175; “Nicolás Monardes”
program of the Andalusian Ministry of
Health, Grant/Award Number: C-0015-2014
Abstract
Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH)
and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which
is associated with increased mortality and morbidity. Somatostatin analogues (SSAs)
represent the primary medical therapy for acromegaly and are currently used as
first‐line treatment or as second‐line therapy after unsuccessful pituitary surgery.
However, a considerable proportion of patients do not adequately respond to SSAs
treatment, and therefore, there is an urgent need to identify biomarkers predictors
of response to SSAs. The aim of this study was to examine E‐cadherin expression
by immunohistochemistry in fifty‐five GH‐producing pituitary tumours and deter-
mine the potential association with response to SSAs as well as other clinical and
histopathological features. Acromegaly patients with tumours expressing low E‐cad-
herin levels exhibit a worse response to SSAs. E‐cadherin levels are associated with
GH‐producing tumour histological subtypes. Our results indicate that the immuno-
histochemical detection of E‐cadherin might be useful in categorizing acromegaly
patients based on the response to SSAs.
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1 | INTRODUCTION
Acromegaly is a rare disease resulting from hypersecretion of growth
hormone (GH) and concomitant insulin‐like growth factor 1 (IGF1)
typically caused by pituitary adenomas termed somatotropinomas.
GH and IGF1 excess are associated with increased mortality and
morbidity,1 and thus, the reduction in GH and IGF1 levels is consid-
ered the main therapeutic goal in acromegaly.
Consensus guidelines recommend somatostatin analogues (SSAs)
as the therapy of choice for pharmacological treatment of acrome-
galy either as adjuvant therapy in patients after unsuccessful pitu-
itary surgery or when surgery is considered not feasible.2 However,
the response to SSAs treatment is largely variable.3-5 Recent
prospective studies have shown success rates for SSAs (20%‐40% of
patients) lower than initially reported (recently reviewed in6). While
differences in patient selection and definitions of response to treat-
ment may partly account for these discrepancies among published
studies, there is certainly considerable variability in the efficacy of
SSAs among patients in each individual study. Thus, the discovery of
the factors involved in resistance to SSAs and/or in predicting
patient response to SSAs treatment might help to individualize thera-
peutic treatments in acromegaly patients.
A number of histopathological and molecular markers of response
to SSAs have been proposed during the last decades but none has
been incorporated into routine clinical practice or in clinical guidelines
for the management of acromegaly patients. Molecular markers such
as AIP, ZAC1 and RKIP and, prominently, somatotastin receptor sub-
types (SSTRs) has been analysed in GH‐producing pituitary adenomas
at the mRNA or protein level.7-13 Another molecular marker associated
with SSAs response is the accumulation of E‐cadherin.14 E‐cadherin is
a cell adhesion protein located at the cytoplasmic membrane and
reported to work as a tumour suppressor. Loss of E‐cadherin expres-
sion is associated with increased invasive and metastatic ability in a
variety of tumours such as breast and lung tumours.15,16 The link
between loss of E‐cadherin and invasive tumour behavior might be
related to the induction of epithelial‐to‐mesenchymal transition (EMT)
commonly observed in the most advanced phases of these tumours.
Thus, E‐cadherin down‐regulation is considered a hallmark of EMT.
Decreased expression of E‐cadherin in pituitary (including GH‐produ-
cing) adenomas has been previously reported.14,17-20 However, the
association between the loss of E‐cadherin expression and aggressive-
ness of GH‐producing tumours has yielded conflicting results.14,17-20
E‐cadherin expression levels are also correlated with GH‐producing
tumour histological subtypes. Thus, whereas high E‐cadherin expres-
sion levels are found in densely granulated somatotroph adenomas
(DGSAs) tumours, low or absent E‐cadherin expression is observed in
sparsely granulated somatotroph adenomas (SGSAs).21-25 Of note, the
granulation pattern of GH‐producing tumours is considered a histolog-
ical marker of response to SSAs treatment with SG somatotropinomas
presenting a worse response to SSAs treatment.26 Despite all these
findings, the potential association between E‐cadherin expression and
SSAs response in GH‐producing tumours has been barely studied to
date.14 Fougner et al14 reported that loss of membranous E‐cadherin
expression and concomitant translocation of E‐cadherin to the nucleus
was associated with resistance to SSAs treatment in GH‐producing
tumours. In this study, E‐cadherin expression was assessed by
immunohistochemistry (IHC) using two different antibodies directed
against either the intracellular or the extracellular domain of the pro-
tein. Importantly, their results revealed that a significant association
between E‐cadherin expression and response to SSAs could only be
found when E‐cadherin accumulation was evaluated with the intracel-
lular domain antibody.14 Therefore, the choice of antibody may
severely influence the potential predictive value of E‐cadherin accu-
mulation for the SSAs treatment response in acromegaly patients.
Here, we performed a precise histological and immunohistochemical
E‐cadherin examination in GH‐producing pituitary tumours using an
automated system and an E‐cadherin antibody widely used in diagnostic
pathology. Our aim was to identify the potential association between
the response to SSAs treatment and E‐cadherin expression. Moreover,
we analysed the relationship between E‐cadherin expression and GH‐
producing histological subtypes as well as SSTRs expression.
2 | MATERIAL AND METHODS
2.1 | Patients and samples
The study population consisted of 55 acromegaly patients who were
evaluated retrospectively and identified from a series of 152 acro-
megaly patients who underwent transsphenoidal surgery in the Vir-
gen del Rocío University Hospital between 1998 and 2014.13 The
diagnosis was based on clinical and biochemical features and
confirmed immunohistochemically by an experienced pathologist.
Fifty‐five patients whose archival tissue was available and of enough
quality for IHC were included. These 55 patients have been
described in a previous study comprising a larger cohort of acrome-
galy patients.13 The usual clinical practice in our hospital is that all
acromegaly patients are treated with SSAs (octreotide or lanreotide)
while waiting for surgery27 regardless of their responsiveness to
SSAs. Thus, all acromegaly patients included in this study have been
preoperatively treated with SSAs. Indeed, seven patients were
excluded for this study because of either lack of preoperative treat-
ment or preoperative treatment with dopamine agonists (three and
four patients, respectively). Patients were treated with SSAs until the
day before surgery. After surgery, patients remained without SSAs
treatment until evaluation for surgical remission, performed at least
3 months after surgery following acromegaly guidelines.2 If patients
were considered not cured based on clinical and biochemical data,
SSAs treatment was resumed. No patient received radiotherapy
before surgery. Of the 55 patients, it was possible to obtain reliable
biochemical data to evaluate the response to SSAs treatment from
41 patients either before surgery (27) or as adjuvant after unsuc-
cessful surgery (14). Missing data were because of incomplete fol-
low‐up. Twenty‐eight patients were treated with octreotide long‐
acting release (30 mg) and 13 with lanreotide autogel (120 mg).
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Responsiveness to SSAs was assessed by per cent IGF1 reduction
after 3 and 6 months of treatment from the time of diagnosis (pre-
operative therapy) or from the time of surgical failure evaluation (ad-
juvant therapy). An IGF1 per cent reduction higher than 50% was
considered positive response. Disease control was also assessed
according to consensus criteria.28
Percentages above the upper limit of normal (%ULN) for age‐
and gender‐matched IGF1 levels were calculated. Tumour size and
cavernous sinus invasion data were obtained from magnetic reso-
nance images. Cavernous sinus invasion was evaluated using the
Knosp classification.29 Knosp grade 3 and 4 were defined as inva-
sive. For RNA extraction, a piece of the pituitary tumour was imme-
diately frozen after surgery removal on dry ice and stored at −80°C
until assayed. This study was conducted following the ethical stan-
dards of the Helsinki Declaration of the World Medical Association
and approved by the IBiS‐Virgen del Rocio Hospital Ethics Commit-
tee. Written informed consent was obtained from each participant
or relative in case of autopsy.
2.2 | Histopathology and immunohistochemistry
The construction of the tissue microarray (TMA) containing formalin‐
fixed paraffin‐embedded tissues from 55 GH‐secreting pituitary ade-
nomas has been previously reported.13 Normal pituitary tissue
included in the TMA was obtained from the HUVR‐IBiS BioBank. GH‐
producing histological subtypes were identified using cytokeratin
CAM5.2 immunostaining (Cell Marque, Sigma, Madrid, Spain) with an
automated immunostainer system (Ventana Medical systems, Roche,
Basel, Switzerland) and histological characteristics. DGSAs were
defined by immunostaining of CAM5.2 in a diffuse perinuclear pattern
in more than 70% of tumour cells. SGSAs were defined as paranuclear,
spherical pattern of CAM5.2 in more than 70% of tumour cells. SGSAs
usually exhibit weaker GH immunoreactivity than DGSAs. Immunohis-
tochemical analysis for E‐cadherin was performed using an E‐cadherin
mouse monoclonal antibody directed against the intracellular domain
of the protein (ready‐to‐use, clone 36, VENTANA, Roche, catalogue
number 790‐4497) with an automated immunostainer system (VEN-
TANA, Roche) following the manufacturer's specifications. The adeno-
mas were assessed in a semiquantitatively scored blindly by two
researchers and classified on a three‐tier scale from 1 to 3: score 1, no
or extremely low immunoreactivity; score 2, mild to moderate mem-
branous accumulation (immunoreactivity in <50% of tumour cells);
and score 3, extensive membranous accumulation (immunoreactivity
in more than 50% of tumour cells). This score system is similar to that
used for SSTR scoring.13,30 Bright‐field images were captured using a
BX‐61 microscope (Olympus, Madrid, Spain).
2.3 | RNA isolation, reverse transcription and
analysis of gene expression by quantitative real‐time
PCR
Somatostatin receptor (SSTR1‐SSTR5) and dopamine receptor
(DRD1‐DRD5) expression by quantitative real‐time PCR (qPCR) in
the 55 patients included in this study have been previously anal-
ysed.13 Technical details on RNA extraction, reverse‐transcription
and qPCR quantification have been described elsewhere.31-33 Gene
expression values were normalized to beta‐actin mRNA levels. We
have found beta actin to be a housekeeping gene with stable expres-
sion in pituitary adenomas, as described in previous studies from our
group.13,32,34
2.4 | Statistical analysis
Normality of the data was tested using the Kolmogorov‐Smirnov
test. The categorical variables are described as percentages and fre-
quencies. Normally distributed data are presented as means ± SD
unless noted otherwise. For non‐normally distributed data, median
values with interquartile ranges (IQR) are shown. Data were analysed
using Mann‐Whitney and Kruskal‐Wallis test for nonparametric vari-
ables and ANOVA and Student's t test for parametric variables. For
categorical variables, chi‐square was used. Statistical analysis was
performed using SPSS software version 23.0 for Windows (SPSS,
Chicago, IL, USA). P values <0.05 were considered statistically signif-
icant.
3 | RESULTS
3.1 | Patient and sample characteristics
A total of 55 GH‐producing tumours from acromegaly patients were
studied. The baseline clinical characteristics of the study population
are shown in Table 1. All patients underwent transsphenoidal sur-
gery. Forty‐seven (85.4%) tumours were macroadenomas. Ten
(18.2%) of the adenomas displayed both GH and PRL expression
while the remaining 45 were pure GH‐producing tumours.
3.2 | E‐cadherin expression assessed by IHC in
GH‐secreting adenomas
Robust membranous E‐cadherin staining was observed in normal
human pituitary (Figure 1A). However, not all pituitary cells were
positive for E‐cadherin, in agreement with previous studies.20 Repre-
sentative images of E‐cadherin immunoreactivity in normal pituitary
and the different IHC semiquantitative scores in somatotropinomas
TABLE 1 Baseline characteristics of the study cohort
Characteristics
Sex (% female) 52.7%
Age at diagnosis (years, median, IQR) 39 (32‐47)
Maximum tumour diameter at diagnosis (mm,
median, IQR)
20 (12.8‐29)
GH at diagnosis (ng/mL, median, IQR) 21.4 (8‐40)
IGF1 at diagnosis (% ULN, median, IQR) 260.3 (202.8‐311.1)
Data are presented as median with interquartile ranges (IQR). ULN, upper
limit of normal for age‐ and gender‐matched IGF1 levels.
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are shown in Figure 1A. Twenty‐eight tumours displayed none or
extremely low, negligible membranous staining. Ten tumours dis-
played mild to moderate membranous immunoreactivity (<50% of
the tumour cells). The remaining 17 tumours displayed strong mem-
branous immunoreactivity in more than 50% of the cells (Figure 1B).
No nuclear immunoreactivity was observed in any of the pituitary
tumours.
3.3 | Association between E‐cadherin expression
and baseline biochemical and clinical characteristics
At baseline, tumour size was significantly different among the three
E‐cadherin IHC scores (P = 0.003), namely it was lower in the score
3 than in scores 2 and 1 (Figure 1C). The median tumour size for
score 1 was 23 mm (IQR, 15‐30), 23.5 mm (IQR, 15‐31.8) for score
2 and 12 (IQR, 10‐17.5) for score 3. Tumours with score 3 were less
likely to be invasive than tumours with score 2 or 1 (Figure 1D). We
did not find statistically significant differences in sex, age and GH or
IGF1 levels (assessed by per cent increase from upper limit of nor-
mal) among the three different E‐cadherin IHC scores.
3.4 | Association between response to
somatostatin analogue treatment and E‐cadherin
expression
Clinical data to conclusively establish the response to SSAs were
available for 41 patients at 3 months of treatment (27 before sur-
gery and 14 as adjuvant therapy) and for 36 patients after 6 months
of treatment (19 before surgery and 17 as adjuvant therapy). As no
differences in the response to SSAs between patients treated preop-
eratively or as adjuvant therapy (both at 3 and 6 months after treat-
ment) were observed, we decided to analyse all the response data as
one single group.
Median IGF1 per cent reduction at 3 and 6 months was 26.5%
(IQR, 2.3‐49.3) and 37.9% (IQR, 4.7‐53.9), respectively. Twelve
patients responded to SSAs (IGF1 per cent reduction higher than
50%) at three (29.3%) and six (33.3%) months, respectively. No
differences were observed regarding age, sex, tumour size and GH
and IGF1 levels at diagnosis between patient responders and non‐-
responders either at 3 or 6 months after treatment. In contrast, a
marked difference in IGF1 per cent reduction after SSAs treatment
F IGURE 1 Immunohistochemical
detection of E‐cadherin in GH‐producing
tumours. A, Representative images of E‐
cadherin immunohistochemical (IHC) scores
in normal human pituitary and
somatotropinomas. Score 1, no or very low
immunoreactivity; score 2, membranous
immunoreactivity in <50% of cells; score 3,
membranous immunoreactivity in more
than 50% of cells. Scale bar: 100 μm. B,
Percentage of somatotropinomas for each
E‐cadherin IHC score. C, Comparison of
tumour size with the different E‐cadherin
IHC scores. Data points represent values
for each individual patient. Mean and SEM
are also displayed. The Kruskal‐Wallis test
was used for comparison among the three
scores and the Mann‐Whitney test for
post hoc comparisons. D, Percentage of
invasive tumours compared to E‐cadherin
IHC score. The chi‐square test was used.
*P < 0.05; **P < 0.01
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was found at both 3 and 6 months of treatment among the three
E‐cadherin IHC scores (P = 0.004 and 0.006, respectively) (Fig-
ure 2A,B). Specifically, a lower IGF1 per cent reduction was
observed at 3 and 6 months in the score 1 compared to scores 2
and 3 (P = 0.008 and 0.005, for 3 and P = 0.006 and 0.012, for
6 months, respectively) (Figure 2A,B). No differences in IGF1 per
cent reduction were found between scores 2 and 3, either at 3 or
6 months after treatment (Figure 2A,B). At 3 months of treatment,
the median IGF1 per cent reduction for score 1 was 4.1 (IQR, −0.5
to 31.2), 42.5 (IQR, 26.5‐52.6) for score 2, and 45.8 (IQR, 14‐58.4)
for score 3. At 6 months of treatment, the median IGF1 per cent
reduction for score 1 was 8.9 (−0.6 to 37.9), 44.5 (IQR, 33.4‐61.7)
for score 2, and 54.8 (IQR, 14‐64.5) for score 3. Only two of the
patients with tumours with score 1 (out of 20) were responders at
3 months (Figure 2C) and only one tumour was responder at
6 months (Figure 2D). At 3 months of treatment, 50% of adenomas
with a score of 2% and 45.5% of adenomas with a score of 3 were
considered responders (Figure 2C). At 6 months of treatment, 37.5%
of adenomas with a score of 2% and 72.7% of adenomas with a
score of 3 were considered responders (Figure 2D). Disease con-
trol28 by SSAs treatment at 6 months was achieved in 33.3% of
patients (12 out of 36). Only two of the patients with tumours with
score 1 (out of 17), while 5 patients (out of 8; 62.5%) classified as
score 2, and 5 (out of 11; 45.5%) classified as score 3 achieved dis-
ease control (chi‐square test, P = 0.025).
Importantly, there was no difference in the duration of preopera-
tive SSA treatment between responder (8, IQR, 3‐11.3 at 3 months
and 8.5, IQR, 6.3‐13.5 at 6 months of treatment) and non‐responder
patients (6, IQR, 3‐10.5 at 3 months and 5.5, IQR, 2.3‐10.6 at
6 months of treatment) (P = 0.57 and 0.22 at 3 and 6 months,
respectively) that could have potentially affected E‐cadherin
expression.
3.5 | Relationship between E‐cadherin and
dopamine and somatostatin receptor expression
We have previously described an association between the response
to SSAs treatment and the expression of SSTR1 and SSTR2 as well
F IGURE 2 Insulin‐like growth factor 1 (IGF1) per cent reduction after somatostatin analogues (SSAs) treatment and E‐cadherin score. A,
Comparison of IGF1 per cent reduction after 3 mo of SSAs treatment with the different E‐cadherin immunohistochemistry (IHC) scores. B,
Comparison of IGF1 per cent reduction after 6 mo of SSAs treatment with the different E‐cadherin IHC scores. Data points represent values
for each individual patient. Mean and SEM are also displayed. The Kruskal‐Wallis test was used for comparison among the three scores and
the Mann‐Whitney test for post hoc comparisons. C, Percentage of patients responsive to SSAs treatment after 3 mo compared to E‐cadherin
IHC score. The chi‐square test was used. D, Percentage of patients responsive to SSAs treatment after 6 mo compared to E‐cadherin IHC
score. The chi‐square test was used. *P < 0.05; **P < 0.01; ***P < 0.001
3092 | VENEGAS‐MORENO ET AL.
as DRD4 and DRD5, as assessed by qPCR.13 However, no differ-
ence in the gene expression levels of these receptors (or, for that
matter, any other measured SSTRs and DRDs) was found among
the different E‐cadherin IHC scores (data not shown). We also anal-
ysed the potential association between E‐cadherin expression and
SSTR protein levels as evaluated by IHC. Again, no association was
found between E‐cadherin IHC scores and SSTR2 and SSTR3 IHC
scores (P = 0.22 and 0.79, respectively). However, an intriguing
inverse relationship was found between E‐cadherin IHC scores and
SSTR5 grading scores (P = 0.012). GH‐producing tumours with E‐
cadherin score of 1 were more likely to have a SSTR5 IHC score
of 3 and less likely to have a SSTR5 IHC score of 1 (Table 2). Con-
versely, tumours with E‐cadherin score of 3 were less likely to have
a SSTR5 IHC score of 3 and more likely to have a SSTR5 IHC
score of 1 (Table 2).
3.6 | Association between adenoma granulation
pattern and E‐cadherin expression
It has been reported that E‐cadherin expression levels differ in GH‐
producing tumour histological subtypes.21-24 To confirm this notion in
our series of 55 tumours, granulation pattern was examined. Twenty‐
four tumours (48%) were SGSAs, 26 tumours (52%) were DGSAs. His-
tologic subtyping could not be established in five tumours, because of
the absence of cytokeratin CAM5.2 immunostaining and these cases
were excluded from further analysis. E‐cadherin expression was low or
absent in most of SGSAs (Figure 3A) while most of DGSAs displayed
strong E‐cadherin expression (score 2 or 3) (Figure 3A). We analysed
whether histological subtypes of GH‐producing tumours displayed dif-
ferences in the response to SSAs treatment. The IGF1 per cent reduc-
tion at both 3 (Figure 3B; P = 0.027) and 6 months after treatment
(Figure 3C; P = 0.015) was lower in SGSAs compared to DGSAs. Only
one SGSAs (of 16) was responder at 6 months while more than half
(nine of 16) of DGSAs were responders (P = 0.006). At 3 months of
treatment, no significant differences in terms of responders were
observed between SGSAs and DGSAs.
4 | DISCUSSION
In this study, E‐cadherin expression was assessed by IHC in 55
acromegaly patients with GH‐producing tumours, using an auto-
mated system and an E‐cadherin antibody widely used in diagnostic
pathology. In previous studies on pituitary tumours, antibodies
directed against the intracellular or extracellular domain of E‐cad-
herin have been used.14,17 Here, we selected the clone 36 mouse
monoclonal E‐cadherin antibody directed against the intracellular
TABLE 2 Association of E‐cadherin and SSTR5
immunohistochemistry scores
E‐cadherin IHC score
SSTR5 IHC score
1 2 3
1 5a 8 15b
2 3 4 3
3 10b 6 1a
aLower frequency with respect to the other IHC scores in the adjusted
residual analysis (residual was smaller than −1.96, indicating that the
number of cases in that cell is significantly smaller, with a significance
level of P = 0.05).
bHigher frequency with respect to the other IHC scores in the adjusted
residual analysis (residual was higher than 1.96, indicating that the num-
ber of cases in that cell is significantly larger, with a significance level of
P = 0.05).
F IGURE 3 Histological subtypes and response to Somatostatin analogues (SSAs) treatment. A, Percentage of somatropinomas categorized
by histology subtype and E‐cadherin immunohistochemistry score. The chi‐square test was used. *P < 0.05; ***P < 0.001. B, Comparison of
insulin‐like growth factor 1 (IGF1) per cent reduction after 3 mo of SSAs treatment with the different histological subtypes of GH‐producing
tumours. C, Comparison of IGF1 per cent reduction after 6 mo of SSAs treatment with the different histological subtypes of GH‐producing
tumours. In (B,C) data points represent values for each individual patient. Mean and SEM are also displayed. The Mann‐Whitney test was used.
*P < 0.05
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domain of the protein; first because this antibody has been increas-
ingly used in recent years for diagnostic pathology, particularly in
breast and lung tumours.16 Also, because antibodies directed
against the extracellular domain of E‐cadherin have previously failed
to reveal relevant associations with characteristics of clinical inter-
est in acromegaly.14 The reasons for this difference between anti-
bodies that target the extracellular and the intracellular domain of
E‐cadherin is unclear but it might be because of differential cleav-
age and/or internalization of the protein domains14 that it might
also reflect the differential function of both domains.35 Thus, based
on the E‐cadherin IHC pattern observed with the selected antibody,
three types of somatropinomas could be easily identified in our
study: tumours with very low or total absence of E‐cadherin
expression (score 1), tumours with a mild to moderate number of
cells with E‐cadherin membranous accumulation (score 2, <50% of
the tumour cells) and tumours with ample membranous accumula-
tion (score 3, more than 50% of the cells). In our series of GH‐pro-
ducing pituitary tumours, only membranous localization of E‐
cadherin was observed and, in contrast with previous studies,14,17
no nuclear accumulation of E‐cadherin could be detected. This
apparent discrepancy could be because of the specific E‐cadherin
antibody used.36 We observed a similar proportion of GH‐producing
tumours displaying none or very low membranous E‐cadherin
immunoreactivity compared to some studies17,18 but a higher pro-
portion compared to other studies.19,23,37 These discordant results
could be related, at least partly, to differences in patients included
in the studies. In this regard, we found a higher number of SGSAs
in our series. Nevertheless, our study corroborates the variable
expression of E‐cadherin in GH‐producing pituitary tumours previ-
ously described in these studies. We found that tumours with ele-
vated E‐cadherin levels (score 3) were markedly smaller compared
to tumours with score 1 or 2. This difference in tumour size may
explain the marked difference in invasion behavior between
tumours with elevated and low or medium E‐cadherin levels. Our
results are in agreement with previous studies indicating that lower
membranous E‐cadherin levels are associated with aggressive fea-
tures in pituitary tumours.14,17,20
Importantly, our results revealed that loss of membranous E‐cad-
herin localization is associated with poor response to SSAs in acro-
megaly patients, in line with a previous study.14 IGF1 reduction after
3 and 6 months of SSAs treatment was markedly lower in GH‐
secreting tumours with E‐cadherin IHC score 1 compared to tumours
with scores 2 and 3. Furthermore, only 2 of the patients with
tumours with score 1 (of 20) displayed an IGF1 decrease higher than
50% at 3 months of SSAs treatment, and only 1 of 17 at 6 months
after treatment. In contrast, around half of tumours with scores 2
and 3 were non‐responders. Interestingly, no differences in IGF1 per
cent reduction were observed between tumours with score 2 and 3,
despite the marked differences in E‐cadherin accumulation. Collec-
tively, these results would be consistent with the notion that E‐cad-
herin membranous localization is a permissive, but not sufficient,
factor for the efficient response to SSAs treatment in acromegaly
patients.
Tumour expression of SSTR2 seems to be the most consistent
marker determining the response to SSAs in acromegaly (recently
reviewed in 3 and 26). Thus, tumours with low SSTR2 expression
commonly display poor response to SSAs treatment. In support of
this, we recently evaluated systematically the expression of SSTRs
and DRDs in somatotropinomas by qPCR and found an association
between the response to SSAs treatment and SSTR2 but also with
SSTR1, DRD4 and DRD5 expression.13 However, we did not find
here an association between E‐cadherin IHC score and the expres-
sion of these receptors. Similarly, there was no association between
E‐cadherin and SSTR2 scores when both were evaluated by IHC. Of
note, low E‐cadherin levels were associated with poor response to
SSAs treatment, even in patients with high SSTR2 levels. Thus, our
results suggest that E‐cadherin and SSTR2 might be, at least in part,
two independent regulators (and markers) of the response to SSAs.
At variance with our results, a previous report has described a direct
correlation between E‐cadherin and SSTR2 expression in GH‐secret-
ing tumours.14 The reasons for this apparent discrepancy are not
completely clear but may relate to differences in the patients
included in the studies. Thus, all the patients included in our study
received preoperative treatment with SSAs (unlike those patients
in14), and previous studies have suggested that preoperative SSAs
treatment may lead to reduced SSTR2 expression.10,38 Nevertheless,
our previous analysis of this group of tumours has confirmed that
SSTR2 expression adequately discriminates between good and poor
responders to SSA treatment13 results that compare well with those
reported in SSA‐naive patients, thus arguing against a substantial
impact of SSAs preoperative treatment on SSTR2 expression.
Notably, preoperative treatment of GH‐secreting tumours with
SSAs has also been shown to be associated with lower E‐cadherin
levels. However, this effect was only observed when E‐cadherin
expression was measured by Western blotting, not when evaluated
by IHC.14 Hence, as we have evaluated E‐cadherin expression by
IHC, it is not expected that preoperative SSA treatment might have
markedly impacted our results regarding E‐cadherin expression
levels. Thus, the potential relationship, or lack thereof, between
E‐cadherin and SSTR2 in the context of patient response to
SSAs treatment remains unclear and clearly deserves further
investigation.
Intriguingly, we observed a negative association between E‐cad-
herin and SSTR5 expression in GH‐producing tumours. Tumours with
low E‐cadherin score expressed higher levels of SSTR5 while
tumours with high E‐cadherin score displayed lower SSTR5 protein
levels. This unexpected association may be related to the tumour
histological subtypes. In our study, most of the GH‐producing
tumours with absent E‐cadherin expression were SGSAs, and it has
been reported that SSTR5 expression is higher in SGSAs compared
to DGSAs.39 However, it is important to note that not all studies
have observed a difference in SSTR5 expression between SGSAs
and DGSAs.22,40 Finally, while the relationship between E‐cadherin
and SSTR5 expression is poorly know, it is worth noting that the
expression of SSTR5 and some of its truncated variants comprises
the only known markers among SSTRs for worse patient response to
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SSAs.26,31 Hence, it seems that the potential connection negative
linking E‐cadherin and SSTR5 expression (and, perhaps, function)
deserves to be explored in more detail.
As previously reported,21-25 we found E‐cadherin expression
levels are associated with GH‐producing tumour histological sub-
types. SGSAs tumours displayed low E‐cadherin levels while DGSAs
tumour showed high E‐cadherin levels. Our results confirm and fur-
ther expand previous data demonstrating that SGSAs exhibit a poor
response to SSAs treatment.21,41 Indeed, we observed a marked
difference in response to SSAs treatment according to the histologi-
cal subtype; however, this was observed only at 6 months after
treatment. Thus, and at least in our group of tumours, we found the
E‐cadherin expression was a better biomarker of response to SSAs
than histological classification of tumour granulation pattern.
In conclusion, considering that low E‐cadherin levels correlate
with poor response to SSAs in GH‐producing tumours, it seems plau-
sible that E‐cadherin may contribute to mediate SSAs effects in
these tumours. Accordingly, IHC assessment of E‐cadherin might be
useful in categorizing acromegaly patients based on the response to
SSAs.
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